Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent with the Company’s ...

Clinical study results show patients who eliminated foods as determined by the inFoods® IBS test experience significant improvement in IBS Symptoms Including Abdominal Pain Intensity (API) IRVINE, ...

Biomerica, Inc. announced that the American Medical Association's CPT editorial panel has granted a Proprietary Laboratory Analysis (PLA) code for its inFoods® IBS test, which personalizes the ...

inFoods IBS Provides Personalized Diet Therapy for Patients Suffering with Irritable Bowel Syndrome (IBS) Research Finds Patients Following a Personalized Diet Therapy Created with inFoods ® IBS, ...

The inFoods ® IBS test is a novel, non-invasive diagnostic that identifies patient-specific IBS trigger foods that may be contributing to IBS symptoms such as bloating, abdominal pain, diarrhea, and ...

Biomerica, Inc. has announced that a landmark peer-reviewed study published in the June 2025 issue of Gastroenterology shows the inFoods® IBS test is an effective personalized dietary therapy for ...

An elimination diet guided by a novel irritable bowel syndrome (IBS)–specific immunoglobulin G (IgG) assay reduced abdominal pain in a greater proportion of patients with IBS than a sham elimination ...

inFoods ® IBS test is the first of its kind to identify specific foods that can trigger an Irritable Bowel Syndrome (IBS) symptoms IRVINE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc.

Commonwealth Diagnostics International will officially re-launch IBSchek, the first clinically validated blood test for diarrhea-predominant and mixed-type irritable bowel syndrome, at Digestive ...